Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP).

Long acting (LA) drug products extend the effect of a single dose for weeks or months, offering new options for disease prevention and treatment. However, regulatory guidance on LA drug product development and equivalence remains limited. The existin…

Preview only. Read the full abstract at the source